QUANTUM GENOMICS SAS-REGR (ALQGC.PA)

FR0011648971 - Common Stock

0.0721  0 (-1.77%)

Fundamental Rating

1

ALQGC gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 74 industry peers in the Biotechnology industry. Both the profitability and financial health of ALQGC have multiple concerns. ALQGC has a valuation in line with the averages, but it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALQGC has reported negative net income.
In the past 5 years ALQGC always reported negative net income.
ALQGC had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ALQGC's Return On Assets of -84.63% is on the low side compared to the rest of the industry. ALQGC is outperformed by 80.00% of its industry peers.
ALQGC has a Return On Equity of -726.18%. This is in the lower half of the industry: ALQGC underperforms 75.71% of its industry peers.
Industry RankSector Rank
ROA -84.63%
ROE -726.18%
ROIC N/A
ROA(3y)-87.78%
ROA(5y)-71.29%
ROE(3y)-517.57%
ROE(5y)-335.54%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ALQGC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

ALQGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALQGC has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALQGC has more shares outstanding
The debt/assets ratio for ALQGC is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -11.61, we must say that ALQGC is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -11.61, ALQGC is doing worse than 84.29% of the companies in the same industry.
A Debt/Equity ratio of 4.49 is on the high side and indicates that ALQGC has dependencies on debt financing.
ALQGC has a worse Debt to Equity ratio (4.49) than 72.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.49
Debt/FCF N/A
Altman-Z -11.61
ROIC/WACCN/A
WACC7.48%

2.3 Liquidity

ALQGC has a Current Ratio of 2.73. This indicates that ALQGC is financially healthy and has no problem in meeting its short term obligations.
ALQGC has a Current ratio of 2.73. This is comparable to the rest of the industry: ALQGC outperforms 60.00% of its industry peers.
ALQGC has a Quick Ratio of 2.73. This indicates that ALQGC is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ALQGC (2.73) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.73
Quick Ratio 2.73

More info and screens

0

3. Growth

3.1 Past

ALQGC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 87.28%, which is quite impressive.
The Revenue for ALQGC has decreased by -98.34% in the past year. This is quite bad
The Revenue for ALQGC have been decreasing by -79.70% on average. This is quite bad
EPS 1Y (TTM)87.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.58%
Revenue 1Y (TTM)-98.34%
Revenue growth 3Y-79.7%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6121.43%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year1744.53%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALQGC. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 0.02, the valuation of ALQGC can be described as very cheap.
Based on the Price/Forward Earnings ratio, ALQGC is valued cheaper than 100.00% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.41, ALQGC is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 0.02

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALQGC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

QUANTUM GENOMICS SAS-REGR

EPA:ALQGC (10/24/2024, 7:00:00 PM)

0.0721

0 (-1.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-22 2024-10-22
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap5.00M
Analysts34.29
Price Target10.2 (14047.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.02
P/S 496.96
P/FCF N/A
P/OCF N/A
P/B 11.45
P/tB 11.45
EV/EBITDA N/A
EPS(TTM)-0.09
EYN/A
EPS(NY)4.34
Fwd EY6021.43%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.63%
ROE -726.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-87.78%
ROA(5y)-71.29%
ROE(3y)-517.57%
ROE(5y)-335.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 4.49
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.73
Quick Ratio 2.73
Altman-Z -11.61
F-ScoreN/A
WACC7.48%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.58%
EPS Next Y6121.43%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-98.34%
Revenue growth 3Y-79.7%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1744.53%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y89.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3919.47%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A